Chronic immune thrombocytopenic purpura in children: Assessment of rituximab treatment Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Purpura, Thrombocytopenic

abstract

  • Rituximab may be a useful treatment for chronic immune thrombocytopenic purpura in children with a >50% CR rate lasting an average of 13 months, with 9 of 15 CRs ongoing (8 lasted 6 months or longer). There was no substantial toxicity other than transient serum sickness.

publication date

  • February 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.jpeds.2004.09.004

PubMed ID

  • 15689912

Additional Document Info

start page

  • 217

end page

  • 21

volume

  • 146

number

  • 2